Introduction: Interleukin-17 inhibitors are the newest class of monoclonal antibodies
INTRODUCTION
Psoriasis is a common chronic inflammatory skin condition that affects 3-4% of the adult US population [1] . Surveys have shown that despite the availability of topical, oral, and systemic treatments, a substantial portion of patients with psoriasis remain undertreated relative to the severity of their disease, leading to high dissatisfaction rates [2] .
Untreated psoriasis is associated with severe impairment in social, occupational, and overall well-being, with physical and emotional impact that increases with disease severity [2, 3] . Thus, new therapies with enhanced long-term efficacy and safety are needed by dermatologists for the treatment of moderate-to-severe psoriasis.
Ixekizumab is currently one of three biologic agents (along with secukinumab and brodalumab) that target the interleukin (IL)-17 cytokine pathway. IL-17 is a proinflammatory cytokine produced primarily by type 17 helper (TH17) T cells [4] . Specifically, IL-17A, one of the 6 homodimers of IL-17, is considered the most potent isoform in psoriasis development [5, 6] and exerts its effect by binding the IL-17 receptor subunit A (IL-17RA) [7] . Ixekizumab is a humanized monoclonal immunoglobulin G (IgG) 4 antibody that acts by specifically binding to and inhibiting IL-17A, thus inhibiting the inflammatory changes culminating in psoriasis. IL-17 contributes a role in the activation and recruitment of neutrophils, the blockade of neutrophil apoptosis, and the stimulation of psoriasis angiogenesis [6, [8] [9] [10] . Evidence of elevated levels of IL-17 in psoriatic lesions and in the serum of patients with psoriasis further support the role of IL-17 in the pathophysiology of psoriasis [11] [12] [13] [14] [15] .
In the following article, we review the results of the pivotal Phase III trials regarding the efficacy and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. The co-primary endpoints examined include at least a 75% reduction in psoriasis area and severity index (PASI 75) and static physician global assessment (sPGA) of 0 (clear) or 1 (almost-clear) on a 5-point scale by week 12 of treatment. sPGA is a tool used by clinicians to document their impression of disease severity, with scores ranging from 0 (clear) to 4 (severe disease). We also examined the long-term efficacy, up to 60 weeks, in the clinical trials that have been completed to date.
METHODS
We reviewed the published results of the Phase III clinical trials for ixekizumab to determine the percentage of patients with psoriasis who had a positive response to the therapy. To identify all the studies that addressed ixekizumab, we performed an English language literature search from January 2003 to September 2015 using PubMed with any of the following key words: ''ixekizumab'' and ''psoriasis'' or ''IL-17'' and ''psoriasis''. We also reviewed citations within articles to identify relevant resources and examined recent dermatologic posters for preliminary data as well. Pooled measures of efficacy and incidence of adverse events for each medication were calculated by tabulating values from independently conducted studies.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Three major Phase III clinical trials, UNCOVER-1, UNCOVER-2, and UNCOVER-3 (ClinicalTrials.gov identifiers: NCT01474512, NCT01597245, and NCT01646177, respectively) were conducted to evaluate efficacy and safety of different dosing frequencies of ixekizumab compared to placebo [16, 17] . UNCOVER-2 and UNCOVER-3 also compared ixekizumab to etanercept. The comparisons in baseline demographics are shown in Table 1 , while the results from each of these trials are displayed in Table 2 . The differences between the endpoints at week 12 are recorded in Table 3 .
UNCOVER-1

Study Design
This was a prospective, double-blind, multicenter trial that consisted of 1296 patients randomly distributed in a 1:1:1 ratio to receive 80 mg ixekizumab every 2 weeks (Q2W), 80 mg ixekizumab every 4 weeks (Q4W), or placebo, respectively [16] . Patients in the ixekizumab groups received a 160 mg starting dose followed by 80 mg Q2W or Q4W. 
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Q4W Every 4 weeks,
sPGA static physician global assessment
ixekizumab. The proportions of patients with a
Candida infection at 12 weeks were 0.9% and 0.6% for ixekizumab Q2W and ixekizumab Q4W, respectively, compared to 0.5% for placebo. The rates of serious adverse events at 12 weeks were 1.4%, 2.8%, and 1.2% for patients on ixekizumab Q2W, ixekizumab Q4W, or placebo, respectively. However, this data set should be interpreted with caution as results are preliminary and have not yet been peer reviewed. Additionally, comparisons in adverse events are not statistically significant, as the studies are powered to detect differences in efficacy rather than rates of adverse events.
UNCOVER-2
Study Design
This was a prospective, double-blind, multicenter study that consisted of 1224 patients randomly distributed in a 2:2:2:1 ratio to receive 80 mg ixekizumab Q2W, 80 mg ixekizumab Q4W, etanercept 50 mg twice 
POOLED RESULTS
Efficacy
By week 12, each of the three studies demonstrated statistically significant superiority of ixekizumab 80 mg dosed Q2W and ixekizumab 80 mg dosed Q4W over placebo (P\0.001 for all groups compared to placebo). Within these studies, the pooled proportion of patients reaching PASI 75 was 88.7% and 81.6% for ixekizumab 80 mg Q2W and ixekizumab 80 mg Q4W, respectively, compared to 4.4% in those who took placebo (Fig. 1) . The pooled percentages of patients achieving sPGA 0 or 1 were 81.8% and 75.0% for ixekizumab 80 mg Q2W and ixekizumab 80 mg Q4W, respectively, compared to 3.9% in those who took placebo. Ixekizumab was similarly superior to placebo in terms of PASI 90 and PASI 100 (Fig. 1) .
Adverse Events
The pooled proportion of patients who experienced adverse events at 12 weeks in the three studies comparing ixekizumab to placebo was 54.8% among patients taking ixekizumab 80 mg Q2W, 58.8% among patients taking ixekizumab 80 mg Q4W, and 46.8% among patients on placebo. The pooled proportion of patients experiencing a general infection or specifically a Candida infection was 26.9% and 1.4% for those on ixekizumab Q2W, respectively, and 27.5% and 0.6% for those on ixekizumab Q4W, respectively. Of patients on placebo, 22.8% experienced a general infection and 0.5% a Candida infection. For the UNCOVER-2 and UNCOVER-3 trials, the pooled proportion of patients who experienced neutropenia were 8.8% and 8.5% for ixekizumab 80 mg Q2W and ixekizumab 80 mg Q4W, respectively, compared to 2.8% for placebo.
DISCUSSION
The results of Phase III clinical trials reinforce the theory that ixekizumab is an effective agent in the treatment of plaque-type psoriasis. At week 12, the proportion of patients achieving PASI 75 or sPGA scores of 0 or 1 was comparable between each respective dosage among the three trials and far superior to the portion of patients that received placebo (Table 1 ; Fig. 1 ). The extended data from UNCOVER-1 suggest that the trend of positive results was maintained through 60 weeks of treatment. In UNCOVER-2 and UNCOVER-3, ixekizumab 80 mg Q2W and 80 mg Q4W were found to perform significantly better than etanercept 50 mg twice weekly, a contemporary biologic agent currently approved by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe plaque psoriasis., The superiority of ixekizumab is most pronounced in terms of the proportion of patients who achieve PASI 90 and PASI 100 (Table 1) . This is significant because these efficacy endpoints are more substantial than PASI 75 from a patient perspective, as demonstrated by a study finding that patients who achieve PASI 90 or PASI 100 experience greater improvement in quality of life than PASI 75 responders [18] . The availability of this novel, highly efficacious [19, 20] .
In the trials reviewed here, mild and moderate Candida infections were more frequent among patients taking ixekizumab than placebo. However, all Candida infections were mild to moderate in intensity and resolved without discontinuation of treatment. [29] . Recent epidemiologic studies also suggest that treating the systemic inflammatory state associated with psoriasis leads to a reduction of cardiovascular events such as myocardial infarction and stroke [30] .
On a molecular level, elevated levels of IL-17 have been measured in atherosclerotic plaques [31] , which are thought to act in coordination with other proinflammatory cytokines in plaque formation [32] . Moreover, elevated levels of IL-17 are present in patients who suffer from unstable angina and acute myocardial infarction [33] . Taken together, these findings suggest that antagonizing the IL-17 pathway may serve to alleviate the symptoms of psoriatic arthritis and reduce the risk of cardiovascular events in patients with psoriasis [34] .
CONCLUSIONS
Ixekizumab has yielded promising data in terms 
